These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

918 related articles for article (PubMed ID: 35052763)

  • 1. Intestinal Barrier and Permeability in Health, Obesity and NAFLD.
    Portincasa P; Bonfrate L; Khalil M; Angelis M; Calabrese FM; D'Amato M; Wang DQ; Di Ciaula A
    Biomedicines; 2021 Dec; 10(1):. PubMed ID: 35052763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prebiotics targeting gut-liver axis to treat non-alcoholic fatty liver disease.
    Castelnuovo G; Perez-Diaz-Del-Campo N; Guariglia M; Poggiolini I; Armandi A; Rosso C; Caviglia GP; Bugianesi E
    Minerva Gastroenterol (Torino); 2023 Mar; ():. PubMed ID: 36892817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intestinal Barrier Function in the Pathogenesis of Nonalcoholic Fatty Liver Disease.
    Liu L; Yin M; Gao J; Yu C; Lin J; Wu A; Zhu J; Xu C; Liu X
    J Clin Transl Hepatol; 2023 Apr; 11(2):452-458. PubMed ID: 36643028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver Steatosis, Gut-Liver Axis, Microbiome and Environmental Factors. A Never-Ending Bidirectional Cross-Talk.
    Di Ciaula A; Baj J; Garruti G; Celano G; De Angelis M; Wang HH; Di Palo DM; Bonfrate L; Wang DQ; Portincasa P
    J Clin Med; 2020 Aug; 9(8):. PubMed ID: 32823983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of microbiota in nonalcoholic fatty liver disease.
    Di Ciaula A; Bonfrate L; Portincasa P
    Eur J Clin Invest; 2022 Jul; 52(7):e13768. PubMed ID: 35294774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial effects of exercise on gut microbiota functionality and barrier integrity, and gut-liver crosstalk in an
    Carbajo-Pescador S; Porras D; García-Mediavilla MV; Martínez-Flórez S; Juarez-Fernández M; Cuevas MJ; Mauriz JL; González-Gallego J; Nistal E; Sánchez-Campos S
    Dis Model Mech; 2019 Apr; 12(5):. PubMed ID: 30971408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microbiota Dysbiosis and Gut Barrier Dysfunction Associated with Non-Alcoholic Fatty Liver Disease Are Modulated by a Specific Metabolic Cofactors' Combination.
    Quesada-Vázquez S; Bone C; Saha S; Triguero I; Colom-Pellicer M; Aragonès G; Hildebrand F; Del Bas JM; Caimari A; Beraza N; Escoté X
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diammonium Glycyrrhizinate Protects against Nonalcoholic Fatty Liver Disease in Mice through Modulation of Gut Microbiota and Restoration of Intestinal Barrier.
    Li Y; Liu T; Yan C; Xie R; Guo Z; Wang S; Zhang Y; Li Z; Wang B; Cao H
    Mol Pharm; 2018 Sep; 15(9):3860-3870. PubMed ID: 30036479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the gut microbiota with resveratrol: a demonstration of novel evidence for the management of hepatic steatosis.
    Wang P; Wang J; Li D; Ke W; Chen F; Hu X
    J Nutr Biochem; 2020 Jul; 81():108363. PubMed ID: 32388250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target.
    Kessoku T; Kobayashi T; Tanaka K; Yamamoto A; Takahashi K; Iwaki M; Ozaki A; Kasai Y; Nogami A; Honda Y; Ogawa Y; Kato S; Imajo K; Higurashi T; Hosono K; Yoneda M; Usuda H; Wada K; Saito S; Nakajima A
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease.
    Miura K; Ohnishi H
    World J Gastroenterol; 2014 Jun; 20(23):7381-91. PubMed ID: 24966608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease.
    Augustyn M; Grys I; Kukla M
    Clin Exp Hepatol; 2019 Mar; 5(1):1-10. PubMed ID: 30915401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intestinal permeability in human nonalcoholic fatty liver disease: A systematic review and meta-analysis.
    De Munck TJI; Xu P; Verwijs HJA; Masclee AAM; Jonkers D; Verbeek J; Koek GH
    Liver Int; 2020 Dec; 40(12):2906-2916. PubMed ID: 33037768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.
    Kirpich IA; Marsano LS; McClain CJ
    Clin Biochem; 2015 Sep; 48(13-14):923-30. PubMed ID: 26151226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gut Microbiota and NAFLD: Pathogenetic Mechanisms, Microbiota Signatures, and Therapeutic Interventions.
    Hrncir T; Hrncirova L; Kverka M; Hromadka R; Machova V; Trckova E; Kostovcikova K; Kralickova P; Krejsek J; Tlaskalova-Hogenova H
    Microorganisms; 2021 Apr; 9(5):. PubMed ID: 33946843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies.
    Meroni M; Longo M; Dongiovanni P
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31689910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of Probiotics (MCP
    Mohamad Nor MH; Ayob N; Mokhtar NM; Raja Ali RA; Tan GC; Wong Z; Shafiee NH; Wong YP; Mustangin M; Nawawi KNM
    Nutrients; 2021 Sep; 13(9):. PubMed ID: 34579068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of Junctional Adhesion Molecule A Promotes Severe Steatohepatitis in Mice on a Diet High in Saturated Fat, Fructose, and Cholesterol.
    Rahman K; Desai C; Iyer SS; Thorn NE; Kumar P; Liu Y; Smith T; Neish AS; Li H; Tan S; Wu P; Liu X; Yu Y; Farris AB; Nusrat A; Parkos CA; Anania FA
    Gastroenterology; 2016 Oct; 151(4):733-746.e12. PubMed ID: 27342212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peroxisome proliferator-activated receptor-alpha activation and dipeptidyl peptidase-4 inhibition target dysbiosis to treat fatty liver in obese mice.
    Silva-Veiga FM; Miranda CS; Vasques-Monteiro IML; Souza-Tavares H; Martins FF; Daleprane JB; Souza-Mello V
    World J Gastroenterol; 2022 May; 28(17):1814-1829. PubMed ID: 35633911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.